Xerophthalmia is a disease that includes lachrymal gland disorders consisting of the lachrymal gland, ocular surface (cornea, conjunctiva,Meibomian gland), eyelids, and the sensory/motor nerves that connect them, as well as causing inflammation, and although many patients around the world suffer from it, there has been no appropriate treatment until now.

BHD1028 is effective in treating xerophthalmia with anti-inflammatory action and a mechanism of action that stabilizes the aqueous layer and mucin layer by increasing the eye’s production of tears through cell growth that constitutes ocular tissue.

BHD1028 is a competitive disease-modifying drug (DMD) capable of fundamentally and effectively curing and treating xerophthalmia and inflammatory eye diseases by reducing inflammatory cytokines on the ocular surface and in lachrymal glands and increasing goblet cells in the conjunctiva.
It can also resolve the side effects of steroid anti-inflammatory therapeutics and the disadvantages of foreign body sensation in the eyes.